Laurus Labs540222JV deal update
Laurus Labs invests INR 107.8 crore in KRKA Pharma rights issue; 49% holding unchanged
By ScoutQuest · · 1 min read
49%Shareholding percentage in KRKA investment
- Investment Amount
- INR 107.8 crore
- Equity Shares Subscribed
- 107,800,000 equity shares of INR 10/- each
- Shareholding in JV
- remains the same at 49%
- Target
- KRKA Pharma Private Limited
- Transaction
- Investment in joint venture via rights issue (stake maintained)
Laurus Labs invests INR 107.8 crore in KRKA Pharma rights issue; 49% holding unchanged.
Also from Laurus Labs
ESG rating of 82.6 with CareEdge-ESG 1+ symbol assigned by CARE ESG Ratings
14 Oct 2026
Laurus Labs Q2 & H1 FY27 earnings conference call on October 29, 2026, hosted by DAM Capital Advisors
13 Oct 2026
Board meeting on October 29, 2026 to consider September quarter results and interim dividend proposal
13 Oct 2026
More numbers
- Consideration paid for rights issue subscriptionINR 1,078,000,000/-
- Equity shares of KRKA Pharma acquired107,800,000
- Face value per equity share of KRKAINR 10/-
- Total holding in KRKA after investment262,150,000
- Shareholding percentage in KRKA after investment49%
Source: BSE · 14 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.